Sleep Disorder Treatment Drug Market (By Drug Class: Sedative-hypnotics, Benzodiazepines, Dual orexin receptor antagonists, Melatonin receptor agonists, Antidepressants, Others; By Application: Intrinsic sleep disorders [Psychophysiological insomnia, Narcolepsy, Restless legs syndrome, Obstructive sleep apnea syndrome, Others], Extrinsic sleep disorders [Environmental sleep disorder, Food allergy insomnia, Toxin-induced sleep disorder, Others]; By Distribution Channel: Retail pharmacies, Online platforms, Others) - Global Industry Analysis, Market Size, Opportunities and Forecast 2020 - 2027

Category : Healthcare and Pharmaceuticals | Published at : November-2020 | Delivery Format : PDF | Status: Published | Pages : 190

The global sleep disorder treatment drug market is anticipated to grow at a CAGR of around 7.9% during the forecast period 2020 to 2027 and to reach around US$ 29.1 Bn by 2027.

Market Dynamics

Increasing advancements in drug discovery, rising number of patients suffering from chronic diseases across the globe and introduction of innovative drugs are major factors expected to drive the growth of global market. According to U.S. Department of Health & Human Services Insomnia is the most common specific sleep disorder with short term issues reported by about 30% of adults and chronic insomnia by 10% and 25 Million U.S. adults have obstructive sleep apnea.

In addition, major players focus on business development through strategic acquisitions and product launches in order to attract customers and increase the profit share which is expected to boost the growth of target market.

In 2020, Koninklijke Philips N.V. a conglomerate corporation partnered with Indian Sleep Disorders Association (ISDA) in order to offer a six-month online certified course in sleep medicine. The partnership is focused on providing quality treatment for sleep disorders and the company has trained more than 500 sleep technicians and guided the launch of more than 650 sleep labs in the country till date. This is expected to help the company to enhance the business presence and increase the revenue share.

In 2019, Eisai Co., Ltd. a pharmaceutical company in collaboration with Purdue Pharma L.P. submitted an application for new drug to the U.S. Food and Drug Administration (FDA) for lemborexant. The application study is based on investigational agent for sleep-wake regulation, seeking approval for the treatment of insomnia, a sleep-wake disorder. This is expected to help the company to enhance the company profit.

In 2019, Koninklijke Philips N.V. a conglomerate corporation launched a new product Philips NightBalance, a prescription sleep position therapy device designed for patients with positional obstructive sleep apnea (OSA). This product launch is expected to help the company to increase the customer base and enhance the profit ratio.

Government is spending high on development of present healthcare infrastructure along with availability of favorable reimbursement policies are among other factors expected to support the growth of target market.

However, factors such as stringent government regulations related to product approval and side effects of drugs are expected to hamper the growth of global sleep disorder treatment drug market. In addition, lack of developed infrastructure in developing countries is expected to challenge the growth of target market.

High investment for development of innovative products and consumer’s inclination towards adoption of herbal products are factors expected to create new opportunities for players operating in the target market over the forecast period. In addition, increasing partnership and agreements between regional and international players is expected to support the growth of revenue transaction.

Segment Analysis by Region

The market in North America is expected to account for major revenue share in the target market due to increasing government spending on healthcare sector. In addition, high spending by the major players for drug discovery and introduction of novel products is expected to support the growth of target market.

Presence of large number of players operating in the country and focus on business expansion through merger and partnerships is expected to boost the target market growth.

Competitive Landscape

The global market is high highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition.

Report coverage

Market	Global Sleep Disorder Treatment Drug Market
Analysis Period	2016 – 2027
Base Year	2019
Forecast Data	2020 – 2027
Market Stratification	Drug Class, Application, Distribution Channel and Geography
Regional Scope	North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
Report Coverage	Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis

Sleep Disorder Treatment Drug Market Segment Analysis, 2019

The global sleep disorder treatment drug market is segmented into drug class, application, and distribution channel. The sleep disorder segment is bifurcated into sedative-hypnotics, benzodiazepines, dual orexin receptor antagonists, melatonin receptor agonists, antidepressants, and others. Among the drug class the sedative-hypnotics segment is expected to account for major revenue share in the target market. The distribution channel segment is divided into retail pharmacies, online platforms, and others. Among the distribution channel, the online platform is expected to witness faster growth in the target segment.

The players profiled in the report are GlaxoSmithKline plc, Koninklijke Philips N.V., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Cardinal Health, Pfizer Inc, Sanofi, Merck & Co Inc, Becton Dickson and Company, and Natus Medical Incorporated.

Market Segmentation

Market By Drug Class

Sedative-hypnotics

Benzodiazepines

Dual orexin receptor antagonists

Melatonin receptor agonists

Antidepressants

Others

Market By Application

Intrinsic sleep disorders